Pro-oncogenic factors such as hypoxia inducible factor 1 a and vascular endothelial growth factor (VEGF) are increased post-RFA and TARE.85,86 Nevertheless, it is likely that LRTs that promote antitumour immunity would benefit from augmentation by ICI therapy and these responses are tumour-specific.2 Here, VEGFA is linked to neoplasm.